Official Title
COVID-19 Vaccination Detoxication in Low Density Lipoprotein Cholesterol
Brief Summary

The study hypothesizes that SARS-CoV-2 vaccination poisoning hibernates in human host inLow Density Lipoprotein Cholesterol (LDL-C). The clinical trial is a follow-up from theintervention trial with NCT number NCT05711810. It tests the use of Atorvastatin CalciumTablets for detoxification and prevention of blood acidification, and the use of theChinese herb compounded Anti-Viral Granules for the detoxification in the endocrinesystem.

Detailed Description

Not Provided

Active, not recruiting
COVID-19 Stress Syndrome
COVID-19 Vaccine Adverse Reaction
COVID-19-Associated Thromboembolism
COVID-19 Post-Intensive Care Syndrome
COVID-19-Associated Stroke
COVID-19 Respiratory Infection

Combination Product: Atorvastatin Calcium Tablets

The intervention observes the effects of the medicines on the participant's health
without the continued interventions on blood pressure. Rescue medicines will be used once
if the blood pressure rise again beyond the healthy range.
Other Name: Anti-Viral Granules

Eligibility Criteria

Inclusion Criteria:

- People who received COVID-19 vaccinations, or experiencing long-COVID.

Exclusion Criteria:

- People with moderate and severe liver dysfunctions.

Eligibility Gender
Male
Eligibility Age
Minimum: 18 Years ~ Maximum: 65 Years
Countries
China
Locations

Residential Address
Chongqing, Chongqing, China

Not Provided

Yang I. Pachankis
NCT Number
Keywords
Covid-19
SARS-CoV-2
Low Density Lipoprotein Cholesterol
sebum
immune reflex
immunology
Immune Deficiency
immune regulation
detoxification
MeSH Terms
COVID-19
Respiratory Tract Infections
Thromboembolism
Syndrome
Atorvastatin
Calcium